NCT05905497

The Study of Bemnifosbuvir in Healthy Japanese Subjects

A Phase 1, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Bemnifosbuvir in Healthy Adult Japanese Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Atea Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 64 Years
• Healthy volunteers: Accepted

Summary

This study will assess the safety, tolerability and pharmacokinetics (PK) of Bemnifosbuvir in healthy adult Japanese subjects

Conditions

• Healthy Volunteer Study

Interventions

Type	Name	Description
DRUG	Bemnifosbuvir (BEM)	BEM administered BID for 4 days and QD on Day 5 (9 consecutive doses)

Timeline

• Start date: 2023-04-26
• Primary completion: 2023-05-19
• Completion: 2023-05-19
• First posted: 2023-06-15
• Last updated: 2023-06-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study